MOBILE VIEW  | 

LATIN AMERICAN SNAKES CROTALINAE

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) This management encompasses Crotalidae species indigenous to Mexico, Central America and South America.
    B) Please refer to UNITED STATES SNAKES CROTALINAE for information on species indigenous to the United States.

Specific Substances

    1) Varies - See Geographical Location section for more information.

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) BACKGROUND: This management discusses Latin American Pit vipers, including crotalus, bothrops and lachesis. Coral snakes are discussed in a separate management, see CORAL SNAKES.
    B) EPIDEMIOLOGY: Although poorly documented, Bothrops asper remain the medically most important pit viper in Latin America; it is responsible for approximately 50% of snake envenomations in Central America, and 90% in South America. In Brazil, crotalus snakebites (primarily Crotalus durissus terrificus and C.d. collilinneatus) make up only 7.5% of snakebites, but regional differences may exist. In Central America, about 30% to 45% of snakebites do not result in envenomation.
    C) TOXICOLOGY: Venom is modified saliva and complex mixture of proteins. The venom of most of these snakes contains a mixture of neurotoxins, hemotoxins, bungarotoxin, and cytotoxins which are typically responsible for the systemic signs and symptoms. Almost all snake venoms contain hyaluronidase to allow effective diffusion of the venom once injected, as well as sphingomyelinases that cause local tissue destruction.
    D) WITH POISONING/EXPOSURE
    1) CENTRAL AMERICA
    a) BOTHROPS: Local signs and symptoms of Bothrops asper (most common species found) envenomation occur rapidly, and can include swelling, pain, bleeding, ecchymosis and necrosis. Systemic envenomation may result in hemorrhage, coagulopathy, nausea, dizziness, fever, vomiting, hypotension (shock possible), and acute renal failure (secondary to hypovolemia). Tissue necrosis can lead to amputation if there is a delay in care. Neurotoxic or myotoxic effects are not usually associated with crotalinae envenomations in Central America.
    b) CROTALUS D. DURISSUS: Envenomations can produce pain and swelling, moderate to severe cases can result in swelling of the entire extremity. Ecchymosis and bleb formation are common, along with nausea and vomiting. Local tissue necrosis may develop if treatment is delayed, or the bite is left untreated. Neurological effects are rare.
    c) LACHESIS: Bites by Lachesis species are rare in Central America and little clinical information is available. Of the small number of cases, local effects include acute pain, swelling, and bleeding; tissue necrosis is also possible. Systemic effects can include: nausea, vomiting, diarrhea, abdominal pain, epistaxis, oliguria, tachycardia, bradycardia (if severe) and coagulopathy. Deaths secondary to hypotension and shock have been reported.
    2) MEXICO
    a) PIT VIPERS: Bothrops {B. asper}, Crotalus, and Sistrurus are indigenous to Mexico and can produce mild, moderate or severe envenomation depending on the size of the snake and the amount of venom injected. Local symptoms can include pain, swelling and bleeding from the fang marks. Systemic effects can include alterations in mental status, bleeding, coagulopathy, hypotension, severe tachycardia, and respiratory compromise.
    3) SOUTH AMERICA
    a) BOTHROPS JARARACUSSU: Local effects include bleeding at the site of the bite and edema. Necrosis at the site may occur in up to 10% of Bothrops bites, but amputation is rare. Secondary infections can result from bacteria in the buccal flora of the snake. Systemic envenomations from Bothrops may result in hemorrhage, coagulopathy, nausea, dizziness, fever, vomiting, hypotension (cardiovascular shock is possible), and acute renal failure (secondary to hypovolemia).
    b) CROTALUS DURISSUS: C.d. terrificus (rattlesnake) produces both neurotoxic and myotoxic effects. Frequent systemic effects reported with envenomation can include acute respiratory failure, hypotension and shock. Death is most often associated with myoglobinuric acute renal failure.
    c) LACHESIS SPECIES (eg, L. muta) are rarely associated with human bites in South America, but bites by the genus Lachesis (bushmaster) found in the Amazon can produce similar clinical effects as the Bothrops.
    0.2.5) CARDIOVASCULAR
    A) WITH POISONING/EXPOSURE
    1) Hypotension and cardiovascular shock can develop following envenomation.
    0.2.7) NEUROLOGIC
    A) WITH POISONING/EXPOSURE
    1) Neurotoxicity has occurred with envenomations by C. d. terrificus and L. muta (bushmaster) species.
    0.2.8) GASTROINTESTINAL
    A) WITH POISONING/EXPOSURE
    1) Nausea and vomiting are common. Hematemesis, hemoptysis, and melena have occurred secondary to coagulopathies.
    0.2.10) GENITOURINARY
    A) WITH POISONING/EXPOSURE
    1) In Central and South America, acute renal failure is relatively common following Bothrops and Crotalus (c.d. durissus, c.d. terrificus) envenomations.
    0.2.13) HEMATOLOGIC
    A) WITH POISONING/EXPOSURE
    1) Hematologic abnormalities including coagulopathies and bleeding can occur after pit viper envenomations.
    0.2.14) DERMATOLOGIC
    A) WITH POISONING/EXPOSURE
    1) Pit viper envenomations can commonly result in rapid localized swelling, ecchymosis, bleeding and tissue injury. Edema can progress to other areas following Bothrops envenomations.
    0.2.15) MUSCULOSKELETAL
    A) WITH POISONING/EXPOSURE
    1) Rhabdomyolysis and muscle pain can develop. In South America, pit viper (Crotalus spp) envenomations can result in systemic myotoxicity.
    0.2.20) REPRODUCTIVE
    A) There are few published reports of envenomation in pregnant women. Abruptio placenta with fetal demise has been reported in one case of Bothrops envenomation.

Laboratory Monitoring

    A) Monitor the bite site for progression of swelling every 15 minutes.
    B) Monitor serial complete blood count, including platelets, coagulation profile (INR or PT, PTT, fibrinogen, fibrin split products) every 4 hours.
    C) Serum electrolytes, renal function and creatine kinase (CPK).
    D) Laboratory work should be repeated periodically, as indicated. Obtain a urinalysis, and type and hold for cross-match in severe envenomation.

Treatment Overview

    0.4.7) BITES/STINGS
    A) SUPPORT
    1) MILD ENVENOMATION: Dry bites are common. Observe patient carefully for at least 8 to 12 hours for any evidence of progression of local tissue injury, and clinical or laboratory evidence of envenomation.
    2) MODERATE TO SEVERE ENVENOMATION: Patients with progressive local tissue injury, systemic or laboratory evidence of envenomation should be treated with antivenom.
    B) GRADING ENVENOMATION
    1) SUMMARY: Progression of clinical effects should be monitored closely. Every finding should be considered in determining the severity of the poisoning. Pain, swelling, ecchymosis and local tissue changes may be absent or minimal, even after a lethal injection of some rattlesnake venoms.
    2) TRIVIAL ENVENOMATION: Manifestations remain confined to or around the bite area. No systemic symptoms or signs. No laboratory changes.
    3) MINIMAL ENVENOMATION: Manifestations confined to the immediate area of the bite, with minimal edema and erythema immediately beyond that area. Perioral paresthesia may be present, but no other systemic symptoms or signs. No laboratory changes.
    4) MODERATE ENVENOMATION: Manifestations extend beyond immediate bite area. Significant systemic symptoms and signs. Moderate laboratory changes (ie, moderately decreased fibrinogen and platelets, elevated INR, prolonged PT or PTT, and hemoconcentration.
    5) SEVERE ENVENOMATION: Manifestations can involve part or the entire extremity. Serious systemic symptoms and signs. Significant laboratory changes or hemorrhage.
    C) OBSERVATION
    1) Patients who do not require immediate treatment should be observed for a minimum of 8 to 12 hours. Observe the patient carefully for evidence of progression of venom effects. This includes careful sequential measuring of edema (marking the skin at the leading edges of edema with a pen every 15 to 30 minutes, as well as following circumferential measurements allows for simple documentation of progression). Lab studies should be repeated prior to discharge to evaluate for development or worsening of coagulopathy.
    D) ANTIVENOM
    1) Evidence of coagulopathy, rhabdomyolysis, systemic venom effects of progression of local tissue injury are indications for antivenom therapy. There are several specific antivenoms produced for treatment of these species. Contact your local poison control center for assistance in locating the most appropriate treatment. If no specific antivenom is available or if the patient requires immediate treatment, it is reasonable to administer Crotalidae Polyvalent Immune Fab (ovine). Antivenom has the potential to induce acute allergic reactions and should only be administered with careful monitoring and in a setting where anaphylaxis can be treated.
    E) ALLERGIC REACTION
    1) MILD/MODERATE: Antihistamines with or without inhaled beta agonists, corticosteroids or epinephrine.
    2) SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring, and IV fluids.
    F) HYPOTENSION
    1) Infuse 10 to 20 mL/kg isotonic fluid. If hypotension persists, administer dopamine (5 to 20 mcg/kg/min) or norepinephrine (ADULT: Begin infusion at 0.5 to 1 mcg/min; CHILD: Begin infusion at 0.1 mcg/kg/min); titrate to desired response.
    G) RHABDOMYOLYSIS
    1) Administer sufficient 0.9% saline to maintain urine output of 2 to 3 mL/kg/hr. Monitor input and output, serum electrolytes, CK, and renal function. Diuretics may be necessary to maintain urine output. Urinary alkalinization is NOT routinely recommended.
    H) PATIENT DISPOSITION
    1) HOME CRITERIA: There is no role for home management of snake bite.
    2) OBSERVATION CRITERIA: All patients bitten by Latin American snakes should be evaluated in a healthcare facility and observed for 8 to 12 hours.
    3) ADMISSION CRITERIA: Any patient with significant or worsening local effects, or any signs of systemic effects or coagulopathy should be admitted to a healthcare facility for treatment and close monitoring.
    4) CONSULT CRITERIA: A medical toxicologist, toxinologist or poison center should be consulted in the event of a Latin American snake envenomation.
    I) PITFALLS
    1) Attempting to apply ice, tourniquets, electric charges, and sucking the venom out of the wound are highly discouraged. Inadequate period of observation for the development of manifestations of envenomation. Basing treatment on eyewitness identification of the snake.
    J) DIFFERENTIAL DIAGNOSIS
    1) Bites and stings from other venomous animals such as scorpions or spiders.

Range Of Toxicity

    A) ENVENOMATION: A single bite can cause severe or even lethal envenomation. However, about 30% to 45% of pit viper bites in Central American do not result in envenomation.

Summary Of Exposure

    A) BACKGROUND: This management discusses Latin American Pit vipers, including crotalus, bothrops and lachesis. Coral snakes are discussed in a separate management, see CORAL SNAKES.
    B) EPIDEMIOLOGY: Although poorly documented, Bothrops asper remain the medically most important pit viper in Latin America; it is responsible for approximately 50% of snake envenomations in Central America, and 90% in South America. In Brazil, crotalus snakebites (primarily Crotalus durissus terrificus and C.d. collilinneatus) make up only 7.5% of snakebites, but regional differences may exist. In Central America, about 30% to 45% of snakebites do not result in envenomation.
    C) TOXICOLOGY: Venom is modified saliva and complex mixture of proteins. The venom of most of these snakes contains a mixture of neurotoxins, hemotoxins, bungarotoxin, and cytotoxins which are typically responsible for the systemic signs and symptoms. Almost all snake venoms contain hyaluronidase to allow effective diffusion of the venom once injected, as well as sphingomyelinases that cause local tissue destruction.
    D) WITH POISONING/EXPOSURE
    1) CENTRAL AMERICA
    a) BOTHROPS: Local signs and symptoms of Bothrops asper (most common species found) envenomation occur rapidly, and can include swelling, pain, bleeding, ecchymosis and necrosis. Systemic envenomation may result in hemorrhage, coagulopathy, nausea, dizziness, fever, vomiting, hypotension (shock possible), and acute renal failure (secondary to hypovolemia). Tissue necrosis can lead to amputation if there is a delay in care. Neurotoxic or myotoxic effects are not usually associated with crotalinae envenomations in Central America.
    b) CROTALUS D. DURISSUS: Envenomations can produce pain and swelling, moderate to severe cases can result in swelling of the entire extremity. Ecchymosis and bleb formation are common, along with nausea and vomiting. Local tissue necrosis may develop if treatment is delayed, or the bite is left untreated. Neurological effects are rare.
    c) LACHESIS: Bites by Lachesis species are rare in Central America and little clinical information is available. Of the small number of cases, local effects include acute pain, swelling, and bleeding; tissue necrosis is also possible. Systemic effects can include: nausea, vomiting, diarrhea, abdominal pain, epistaxis, oliguria, tachycardia, bradycardia (if severe) and coagulopathy. Deaths secondary to hypotension and shock have been reported.
    2) MEXICO
    a) PIT VIPERS: Bothrops {B. asper}, Crotalus, and Sistrurus are indigenous to Mexico and can produce mild, moderate or severe envenomation depending on the size of the snake and the amount of venom injected. Local symptoms can include pain, swelling and bleeding from the fang marks. Systemic effects can include alterations in mental status, bleeding, coagulopathy, hypotension, severe tachycardia, and respiratory compromise.
    3) SOUTH AMERICA
    a) BOTHROPS JARARACUSSU: Local effects include bleeding at the site of the bite and edema. Necrosis at the site may occur in up to 10% of Bothrops bites, but amputation is rare. Secondary infections can result from bacteria in the buccal flora of the snake. Systemic envenomations from Bothrops may result in hemorrhage, coagulopathy, nausea, dizziness, fever, vomiting, hypotension (cardiovascular shock is possible), and acute renal failure (secondary to hypovolemia).
    b) CROTALUS DURISSUS: C.d. terrificus (rattlesnake) produces both neurotoxic and myotoxic effects. Frequent systemic effects reported with envenomation can include acute respiratory failure, hypotension and shock. Death is most often associated with myoglobinuric acute renal failure.
    c) LACHESIS SPECIES (eg, L. muta) are rarely associated with human bites in South America, but bites by the genus Lachesis (bushmaster) found in the Amazon can produce similar clinical effects as the Bothrops.

Heent

    3.4.3) EYES
    A) WITH POISONING/EXPOSURE
    1) In South America, mydriasis, blindness, and diplopia have occurred following Crotalus envenomations (Meier & White, 1995).

Cardiovascular

    3.5.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Hypotension and cardiovascular shock can develop following envenomation.
    3.5.2) CLINICAL EFFECTS
    A) HYPOVOLEMIC SHOCK
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS
    1) CASE SERIES/BOTHROPS JARARACUSSU: In a series of 29 cases of proven Bothrops jararacussu envenomations, shock and intractable severe hypotension (i.e., blood pressure undetectable in one case) were the main clinical features in 2 fatal exposures. An adult and child died despite large doses of antivenom and aggressive supportive care. Although bites by this species are relatively infrequent, it is suggested that larger snakes (i.e., longer than 50 cm) are more venomous (Milani et al, 1997).
    b) CROTALUS DURISSUS TERRIFICUS
    1) Following a Crotalus durissus terrificus evenomation, a 24-year-old man developed shock which was likely secondary to profuse bleeding that occurred at both the fang marks and venipuncture sites during the first 12 hours (Ekenback et al, 1985).
    c) LACHESIS MUTA (BUSHMASTER)
    1) Episodes of hypotension, bradycardia, and other clinical symptoms commonly associated with shock have been reported within 15 minutes of being bitten by a bushmaster. In regions of Colombia, bushmaster bites have produced hypotension along with sweating and nausea (Jorge et al, 1997).
    B) MYOCARDIAL INFARCTION
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS LANCEOLATUS
    1) CASE REPORT: A 74-year-old man was bitten by a B lanceolatus (Fer-de-lance pit viper) and did not seek help immediately. Two days later, he was found comatose and transported to the hospital with normal vital signs, laboratory studies and a normal angio-MRI. A myocardial infarction was diagnosed based on ECG changes and an elevated serum troponin-1c levels. He was treated in the cardiac care unit with no signs of neurologic improvement. Six days after the bite, the patient developed atrial fibrillation and left ventricular failure and rupture of the papillary muscles of the mitral valve; the patient did not respond to resuscitation efforts. Autopsy revealed diffuse thrombotic microangiopathy, with intimal-medial dissection by thrombi, of the small arteries and arterioles of the heart, mesentery, brain, kidneys and lungs (Malbranque et al, 2008).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) RESPIRATORY FAILURE
    1) WITH POISONING/EXPOSURE
    a) SOUTH AMERICA
    1) South American rattlesnake (Crotalus spp) envenomation can result in acute respiratory failure secondary to neurotoxic or myotoxic activity of the venom. This can result in ventilatory disorders and impaired respiratory muscle function (Meier & White, 1995).
    B) HEMOPTYSIS
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS ASPER
    1) Severe coagulopathy in a 60-year-old man bitten by a Bothrops asper resulted in spontaneous bleeding that included hemoptysis (Kornalik & Vorlova, 1990).

Neurologic

    3.7.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Neurotoxicity has occurred with envenomations by C. d. terrificus and L. muta (bushmaster) species.
    3.7.2) CLINICAL EFFECTS
    A) NEUROTOXICITY
    1) WITH POISONING/EXPOSURE
    a) Cranial nerve dysfunction manifested as ptosis, diplopia, facial muscle paresis, ophthalmoplegia, difficulty swallowing and handling secretions, and difficulty speaking have been reported following envenomation by South American rattlesnakes (ie, C. durissus terrificus and C. d. collilineatus), and L. muta (bushmaster) (Meier & White, 1995a; Torres et al, 1995; Silveira & Nishioka, 1992; Amaral et al, 1980; Ekenback et al, 1985a).
    B) CEREBROVASCULAR ACCIDENT
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS SPECIES
    1) CASE SERIES: In a series of 309 patients bitten by Bothrops species, 8 patients (2.6%) with a mean age of 51.9 years developed a cerebrovascular event (ie, hemorrhagic stroke {n=7}, or ischemic stroke {n=1}). Of the 8 patients, 6 presented 8 hours or more after being bitten. All had evidence of decreased neurologic function on admission (coma or lethargy). Each also had pain and swelling around the bite site, and four had signs of systemic bleeding. CT indicated intracranial hemorrhage in the cerebral hemispheres (n=5), cerebellum (n=1), and the subarachnoid space (n=1). Five of the eight patients died and the remaining 3 developed permanent sequelae (Mosquera et al, 2003).
    a) The authors suggested that the proteins (ie, aspercitin, metalloproteinases, and hemorrhagins) found in the venom led to thrombocytopenia, prolongation of prothrombin and partial thromboplastin times, disseminated intravascular coagulation, and even damage of the blood vessel walls (Mosquera et al, 2003).
    b) BOTHROPS LANCEOLATUS
    1) Three patients died within 4 days of envenomation by Bothrops lanceolatus species. Death was due to massive cerebral infarctions. Thrombotic complications have been reported occasionally following B lanceolatus envenomation (Thomas et al, 1996).
    2) CASE REPORT: A 74-year-old man was bitten by a B lanceolatus (Fer-de-lance pit viper) and did not seek help immediately. Two days later, he was found comatose and transported to the hospital with normal vital signs, laboratory studies and a normal angio-MRI and tetraplegia. A myocardial infarction was diagnosed based on ECG changes and an elevated serum troponin-1c levels. He was treated in the cardiac care unit with no signs of neurologic improvement. Six days after the bite, the patient died. Upon autopsy, myocardial and cerebral infarcts were observed and may have been associated with the presence of diffuse thrombotic microangiopathy involving the arteries and arterioles of the brain and heart, as well as other organs (Malbranque et al, 2008).
    C) NEUROLOGICAL FINDING
    1) WITH POISONING/EXPOSURE
    a) PERSISTENT SYMPTOMS
    1) CROTALUS DURISSUS TERRIFICUS: A man developed persistent neurological symptoms (over a month), after c. d. terrificus envenomation. Symptoms gradually improved following rehabilitative therapy. However, the patient remained weak and incontinent of urine at night. Six months after exposure, the patient reported feeling well, but an electromyogram showed evidence of reinnervation of the motor units, and the action potential of the sensory nerves were still considered low (Ekenback et al, 1985a).

Gastrointestinal

    3.8.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Nausea and vomiting are common. Hematemesis, hemoptysis, and melena have occurred secondary to coagulopathies.
    3.8.2) CLINICAL EFFECTS
    A) GASTROINTESTINAL TRACT FINDING
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Nausea and vomiting are relatively common following moderate to severe pit viper envenomations (Meier & White, 1995).
    b) LACHESIS MUTA
    1) CASE REPORT: A 28-year-old man was bitten on the finger by a L. m. muta (a male, approximately 182 cm long) and developed nausea, vomiting and profuse watery diarrhea within 1 hour of envenomation, along with localized pain and swelling of the digit. Despite antivenom (L. muta venom), antiemetic therapies, and IV hydration, the patient continued to have bilious vomiting, abdominal colic, and repeated episodes of watery diarrhea up to 8 hours after the bite. Symptoms gradually resolved 24 hours after exposure (Jorge et al, 1997).
    a) The authors noted that the gastrointestinal effects reported in this case were distinctive symptoms not usually reported with New World Crotalinae, but more often associated with Old World Viperine species (ie, European adder and Palestine viper). Symptoms may manifest in as little as 15 minutes after envenomation (Jorge et al, 1997).
    B) HEMATEMESIS
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Hematemesis has been reported following envenomations by Bothrops, Lachesis muta and Crotalus durissus terrificus species (Kornalik & Vorlova, 1990; Ekenback et al, 1985).
    b) CROTALUS DURISSUS TERRIFICUS
    1) Hematemesis and melena occurred in a young adult man following a Crotalus durissus terrificus envenomation (Ekenback et al, 1985).

Hematologic

    3.13.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Hematologic abnormalities including coagulopathies and bleeding can occur after pit viper envenomations.
    3.13.2) CLINICAL EFFECTS
    A) PROTHROMBIN TIME ABNORMAL
    1) WITH POISONING/EXPOSURE
    a) INCREASED INR, PROLONGED PT and PTT: Markedly increased INR or prolonged PT and PTT (more than 1 minute) may develop following moderate to severe pit viper (Crotalus, Bothrops, Lachesis) envenomations (Thomas et al, 1996; Amaral et al, 1980; Davidson, 1988; Ekenback et al, 1985a; Kornalik & Vorlova, 1990). Prothrombin times generally return to normal following administration of antivenom.
    b) In South America, alterations in hematologic parameters and bleeding often do not result in clinically significant effects, unless the envenomation is severe (Meier & White, 1995).
    c) CASE REPORTS
    1) LACHESIS (BUSHMASTER): A 28-year-old man, envenomated by a bushmaster pit viper, developed hemorrhagic manifestations characterized by hypofibrinogenemia without thrombocytopenia. Coagulation studies were notable for prolonged prothrombin time (PT) with a normal activated partial thromboplastin time (aPTT). The authors suggested, that consumption of factor VII by circulating venom produced the clinical and laboratory effects observed (Torres et al, 1995).
    B) DECREASED FIBRINOGEN
    1) WITH POISONING/EXPOSURE
    a) DECREASED FIBRINOGEN AND INCREASED FIBRIN SPLIT PRODUCTS: Markedly decreased fibrinogen (undetectable) and/or increased fibrin split products may develop after pit viper (Crotalus, Bothrops asper, Lachesis muta) envenomations (Jorge et al, 1997; Kornalik & Vorlova, 1990; Ekenback et al, 1985a; Crane & Irwin, 1985; Budzynski et al, 1984; Amaral et al, 1980). Decreased fibrinogen, incoagulable blood, and/or increased fibrin split products can develop in the absence of other coagulation abnormalities (ie, normal or increased platelet counts) in some cases of Lachesis muta envenomations (Jorge et al, 1997).
    C) BLOOD COAGULATION PATHWAY FINDING
    1) WITH POISONING/EXPOSURE
    a) The coagulation abnormalities associated with crotalinae envenomation may be resistant to correction with blood products (Budzynski et al, 1984; Burgess & Dart, 1991; Bond & Burkhart, 1997). Coagulopathy is one of the most common presenting symptoms following a major envenomation (60% of patients in one study and 62.5% in another study of envenomated children) (Bucaretchi et al, 2001). Prolonged or recurrent coagulopathy can occur. Close monitoring of hematologic parameters should be ongoing for the first 2 weeks after snakebite.
    D) THROMBOCYTOPENIC DISORDER
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS JARARACA
    1) The presence of a low platelet count upon admission has been associated with severe systemic bleeding in patients envenomated by Bothrops jararaca species. The early use of antivenom is recommended (Santoro et al, 2008).
    E) BLOOD COAGULATION DISORDER
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS JARARACUSSU
    1) CASE REPORT: A woman died within 45 minutes of pulmonary hemorrhage following a Bothrops jararacussu envenomation. At autopsy, evidence of hemorrhage and disseminated intravascular coagulation were present. As compared with other Bothrops species, B. jararacussu (found in the jungles/forests of Brazil) venom has a higher lethal potency. The authors speculated that the rapid onset of symptoms and death may have been due to IV inoculation as noted by a bite mark near the great saphenous vein (Benvenuti et al, 2003).
    2) CASE SERIES: In a retrospective study of 792 snakebites by Bothropoides jararaca presenting to the Vital Brazil Hospital of Paulo Brazil, blood clotting time was abnormal in 457 (59%) patients with 40.8% (n=316) cases reported as incoagulable (Nicoleti et al, 2010).
    b) BOTHROPS LANCEOLATUS
    1) In a case series of Bothrops lanceolatus envenomations, of the 11 patients with thromboses, 5 had no coagulation abnormalities, 3 developed disseminated intravascular coagulopathy, and 3 had thrombocytopenia. Laboratory parameters indicated an increase in fibrinogen levels and aPTT in most patients (Thomas et al, 1996).
    F) THROMBOSIS
    1) WITH POISONING/EXPOSURE
    a) Thrombosis has been reported after Bothrops lanceolaus envenomation. In a series of 50 envenomated patients, 11 developed serious thrombotic complications, including pulmonary emboli (2), cerebral infarction (6), myocardial infarction (1), and concurrent cerebral and myocardial infarction (2) (Thomas et al, 1996).

Dermatologic

    3.14.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Pit viper envenomations can commonly result in rapid localized swelling, ecchymosis, bleeding and tissue injury. Edema can progress to other areas following Bothrops envenomations.
    3.14.2) CLINICAL EFFECTS
    A) EDEMA
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Pit viper envenomations can commonly result in rapid localized swelling. Following severe envenomations, edema may progress along with ecchymosis and local tissue injury. Bothrops and Lachesis species can lead to massive swelling that can include the entire limb (Jorge et al, 1997; Meier & White, 1995). Although not commonly reported, compartment syndrome can develop following envenomation (Franca et al, 2003; Meier & White, 1995).
    b) LACHESIS MUTA
    1) CASE REPORT: A 28-year-old man bitten on the index finger developed almost immediate swelling and pain, which gradually progressed over several hours to include swelling of the entire limb within 6 hours. Despite antivenom therapy (within 2 hours of the bite) and supportive care, the limb and shoulder area remained swollen for 24 hours after the bite. Swelling remained for five days, along with blistering of the hand, but the patient retained full range of motion and no residual necrosis was reported (Jorge et al, 1997).
    c) BOTHROPS AND BOTHROPIDES
    1) In a prospective and transverse study of snakebites by Bothrops and Bothropoides (these include: Bothropoides erythromelas, Bothrops leucurus and Bothropoides neuwiedi) in the State of Paraiba, edema (n=357; 87.1), pain (n=393; 95.9%) and ecchymosis (n=109; 25.9%) were the most common local effects observed. Overall most cases resulted in mild (64.6%) envenomation (Oliveira et al, 2010).
    d) BOTHROPOIDES JARARACA
    1) In a retrospective study of 792 snakebites by Bothropoides jararaca presenting to the Vital Brazil Hospital of Paulo Brazil, most cases (80%) showed no or mild envenomation. Most cases presented with pain (n=651; 82.2%) edema (n=646; 81.6%), and ecchymosis (n=388; 49%) (Nicoleti et al, 2010).
    e) BOTHRIOPSIS TAENIATA
    1) CASE REPORT: A 43-year-old man was bitten by a Bothriopsis taeniata (the snake was identified at the hospital) above the ankle and was admitted about 2.5 hours later with swelling to just below the knee with minimal bleeding. The patient was alert and oriented and laboratory studies showed a slightly elevated creatine kinase and lactate dehydrogenase, but otherwise normal. The patient was treated with anti-Bothrops antivenom and leg swelling resolved within 2 days and the patient was discharged with no sequelae. Bothriopsis tatenia is a rare pit viper found in Brazil (Torrez et al, 2009).
    B) SKIN NECROSIS
    1) WITH POISONING/EXPOSURE
    a) Local tissue necrosis may occur at the bite site of a pit viper (Bothrops, Crotalus, Lachesis muta species), and permanent injury can occur (ie, loss of digits, hands, etc) (Nicoleti et al, 2010; Jorge et al, 1997; Cardoso et al, 1993; Hardy, 1994; Meier & White, 1995). Several days are usually required to define areas of nonviable tissue. Permanent deformity has occurred in some cases of Lachesis muta bites due to the proteolytic enzymes found in the venom (Jorge et al, 1997).
    C) LOCAL INFECTION OF WOUND
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Pit viper envenomations can produce local infection, due to the buccal flora of a snake. Bothrops species in South America have been commonly associated with infection. The most frequent pathogens isolated are gram negative aerobes, Staphylococcus aureus, and anaerobic microorganisms. In Brazil, the rate of infection varies by both species and geographic region (Meier & White, 1995).
    b) BOTHROPS SPECIES
    1) In a case series of 56 children who were envenomated by Bothrops spp and treated with antivenom, one of the main clinical complications observed was local infection in 15.1% (including cellulitis, 9.6%, and abscesses, 5.5%) of cases. Severe envenomations were associated with a higher frequency of local infection (Bucaretchi et al, 2001). In another case series, local abscesses were reported in 5 patients (n=29) following B. jararacucu envenomation and 6 developed local necrosis (one case resulted in amputation) (Milani et al, 1997).
    c) BOTHROPS ASPER
    1) Soft tissue infections have been observed in 11% to 30% of envenomations by Bothrops asper. Cellulitis is usually prominent. Other effects can include impetigo, abscess and fascitis. Infection is more likely to occur following a moderate to severe envenomation and is more likely in patients that develop severe edema, hemorrhage, myotoxicity and necrosis (Otero-Patino, 2009).
    d) LACHESIS MUTA
    1) Infection with gram-negative organisms and clostridial gas gangrene have been reported following Lachesis muta bites (Jorge et al, 1997).
    D) COMPARTMENT SYNDROME
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS ASPER
    1) Compartment syndrome has been observed in 3% of patients envenomated by B asper. In some cases, severe swelling can lead to compartment syndrome especially bites on an extremity (eg, finger, foot) (Otero-Patino, 2009).
    b) BOTHROPS JARARACA
    1) CASE REPORT: A 39-year-old man was bitten by a B jararaca (species identified in the emergency department) on the leg and developed intense local pain and swelling. Within 6 hours of envenomation, the patient received 8 vials of bothropic antivenom for moderate to severe envenomation. Approximately, 8 hours after envenomation, elevated anterior compartment pressures (60 mm Hg) were observed, but improved with antivenom therapy. However, at 20 hours post bite, serum CK levels (3452 Units/L and 6729 Units/L at 40 hours post bite ) were elevated with ongoing pain in the leg. A fasciotomy was performed at 57 hours due to increased anterior intracompartmental pressure (66 mm Hg). His hospital course was further complicated by infection and permanent fibular palsy with foot drop (Bucaretchi et al, 2010).
    E) BLEEDING
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Bleeding at the puncture site is relatively common following pit viper (eg, Crotalus, Bothrops, Lachesis muta) envenomations (Meier & White, 1995)
    b) Persistent bleeding from the fang marks have been reported following Lachesis muta and Crotalus durissus terrificus envenomations secondary to coagulopathy (Jorge et al, 1997; Ekenback et al, 1985). In South America, Bothrops species can produce bleeding, but it is usually not of clinical significance (Meier & White, 1995).

Musculoskeletal

    3.15.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Rhabdomyolysis and muscle pain can develop. In South America, pit viper (Crotalus spp) envenomations can result in systemic myotoxicity.
    3.15.2) CLINICAL EFFECTS
    A) RHABDOMYOLYSIS
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Rhabdomyolysis and alterations in serum creatine kinase are possible with Crotalus envenomations. In South America, if rhabdomyolysis is present, myotoxicity is also possible (Meier & White, 1995).
    b) CASE REPORTS
    1) Severe elevations in CPK and significant rhabdomyolysis occurred with Crotalus durissus terrificus envenomation in an adult and child, despite antivenom therapy. At autopsy, rhabdomyolysis was evident in both cases (Azevedo-Marques et al, 1985).
    B) MUSCLE NECROSIS
    1) WITH POISONING/EXPOSURE
    a) MYOTOXICITY
    1) SOUTH AMERICA: Following pit viper envenoming (eg, in particular Crotalus durissus), systemic myotoxicity can develop. Initial symptoms usually include muscle pain which can be severe, along with myoglobinuria (red or dark urine) and evidence of rhabdomyolysis (increased serum creatine kinase {especially CK(3) and CK(2)}). Myoglobinuric acute renal failure is the most common cause of death in Crotalus envenomations (Meier & White, 1995a).
    a) CASE SERIES: Muscle necrosis in the contralateral extremity (ie, leg) has been demonstrated on biopsy in 5 patients with C. durissus terrificus envenomations (Rossi et al, 1989). All had elevations of CPK, LDH and AST, as well as, myoglobinuria.
    2) CENTRAL AMERICA: Localized myonecrosis frequently develops after pit viper envenomation, and if extensive can result in significant pain. In most cases, myonecrosis is a result of myotoxins having a phospholipase A(2) structure, which can produce muscle cell damage by disrupting the integrity of skeletal muscle cells. However, evidence of systemic myotoxicity usually does not develop (Meier & White, 1995a).

Immunologic

    3.19.2) CLINICAL EFFECTS
    A) IMMUNE SYSTEM FINDING
    1) WITH POISONING/EXPOSURE
    a) LACK OF EFFECT: In a study of children bitten by snakes of the Bothrops species (B. asper and B. lateralis) there was no correlation found between elevated serum cytokine concentrations, and the severity of the envenomation or outcome (Avila-Aguero et al, 2001).

Reproductive

    3.20.1) SUMMARY
    A) There are few published reports of envenomation in pregnant women. Abruptio placenta with fetal demise has been reported in one case of Bothrops envenomation.
    3.20.3) EFFECTS IN PREGNANCY
    A) PLACENTAL DISORDER
    1) CASE REPORT - Abruptio placenta with fetal demise developed in a 32 weeks pregnant woman 6 hours after being bitten by Bothrops jararaca (Zugaib et al, 1985).

Genitourinary

    3.10.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) In Central and South America, acute renal failure is relatively common following Bothrops and Crotalus (c.d. durissus, c.d. terrificus) envenomations.
    3.10.2) CLINICAL EFFECTS
    A) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) Acute renal failure is relatively common following Bothrops spp and some Crotalus spp (ie, C. durissus durissus, C. durissus terrificus) envenomations. Its presence is likely multifactorial, and has been associated with the development of myoglobinuria (most common cause), rhabdomyolysis or prolonged hypotension (Otero-Patino, 2009; Pinho et al, 2008; Milani et al, 1997; Amaral et al, 1980; Azevedo-Marques et al, 1985; Caiaffa et al, 1994; Avila et al, 1980; Hardy, 1994; Rosado-Lopez & Laviada-Arrigunaga , 1977).
    b) CENTRAL AMERICA
    1) In Central America, the development of renal failure is secondary to several factors: tubular necrosis secondary to ischemia, direct effect of venom on the kidneys, and inadequate tissue perfusion secondary to hypovolemia. Although localized myonecrosis can occur, rhabdomyolysis or myoglobinuria (even in severe cases) have not been reported in this region (Meier & White, 1995).
    c) SOUTH AMERICA
    1) CROTALUS and BOTHROPS SPECIES: In South America, myoglobinuric acute renal failure is the most common cause of death in Crotalus envenomations. The myotoxic effects (myoglobin liberation and excretion in the urine) and possible nephrotoxic effects of the venom likely contribute to the clinical effects observed. The development of acute renal failure is dependent on the severity of the envenomation and timing of antivenom therapy. Within the first 48 hours, acute tubular necrosis with oliguria or anuria can develop (Meier & White, 1995).
    a) MECHANISM: Bothrop venom-induced acute renal failure is likely multifactorial and has been associated with the direct action of venom on the kidneys, to its hypotensive effects, myoglobinuria, hemoglobinuria and glomerular microthrombi deposit (Rodrigues Sgrignolli et al, 2011).
    2) CHARACTERISTICS:
    a) BOTHROPS: Bites typically produce severe oliguria and an increase in serum creatinine levels which may lead to renal failure requiring dialysis (Rodrigues Sgrignolli et al, 2011; Pinho et al, 2008). The need for dialysis may vary from 33% to 75% of Bothrops cases (Pinho et al, 2008). Early treatment includes adequate hydration and specific antivenom in adequate doses (Rodrigues Sgrignolli et al, 2011).
    b) CROTALUS: Acute renal injury usually occurs within the first 24 to 48 hours. It is suggested that a Crotalus envenomation can produce renal proximal tubule cell injury. Mortality rates associated with acute renal injury have ranged from 8% to 17%, with most victims being young and healthy prior to envenomation (Pinho et al, 2008).
    3) PREDICTIVE FINDINGS: In a study of 87 victims of South American rattlesnake (Crotalus durissus terrificus, C. d. collilineatus and others) envenomation, myalgia and neurotoxic facies were predictive of renal failure in patients older than 40 years (Silveira & Nishioka, 1992).
    a) PREVALENCE: The prevalence of acute renal injury associated with Crotalus envenomations ranges from 10% to 29% and ranges from 1.6% to 38.5% for Bothrops envenomations, respectively (Pinho et al, 2008).
    b) INCIDENCE: In a review, the mortality rate of Bothrops venom-induced acute renal failure ranged from 13% to 19% (Pinho et al, 2008; Rodrigues Sgrignolli et al, 2011).
    c) BOTHROPS JARARACUSSU: In 29 cases of confirmed B. jararacucu bites, 4 patients developed renal failure. Of 3 patients that died, 2 had evidence of acute renal tubular necrosis, along with cerebral edema, hemorrhage and systemic disseminated intravascular coagulation at autopsy (Milani et al, 1997).
    B) BLOOD IN URINE
    1) WITH POISONING/EXPOSURE
    a) Hematuria may develop in patients with coagulopathy or thrombocytopenia. It has been reported following Bothrops and Lachesis muta envenomations (Jorge et al, 1997; Kornalik & Vorlova, 1990; Amaral et al, 1980).

Acid-Base

    3.11.2) CLINICAL EFFECTS
    A) METABOLIC ACIDOSIS
    1) WITH POISONING/EXPOSURE
    a) BOTHROPS
    1) CASE SERIES/BOTHROPS JARARACUSSU: In a series of 29 cases of Bothrops jararacussu envenomations, metabolic acidosis developed in two patients that died from envenomation. In the first case, a 3-year-old girl developed intractable metabolic acidosis (pH 6.65, bicarbonate 3.5 mmol/L), along with shock, respiratory failure and coma. Despite antivenom and aggressive care, the child died within 19 hours of envenomation (Milani et al, 1997).
    a) In the other case, evidence of metabolic acidosis (pH 7.2, bicarbonate 18.5 mEq/L) did not develop until 3 days after envenomation in a 65-year-old man who was given anti-Bothrops antivenom shortly after admission. He died 105 hours after being bitten from refractory hypotension.

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Monitor the bite site for progression of swelling every 15 minutes.
    B) Monitor serial complete blood count, including platelets, coagulation profile (INR or PT, PTT, fibrinogen, fibrin split products) every 4 hours.
    C) Serum electrolytes, renal function and creatine kinase (CPK).
    D) Laboratory work should be repeated periodically, as indicated. Obtain a urinalysis, and type and hold for cross-match in severe envenomation.
    4.1.2) SERUM/BLOOD
    A) HEMATOLOGIC
    1) A complete blood count including platelet count should be ordered and repeated periodically (every 6 hours or as clinically indicated).
    B) COAGULATION STUDIES
    1) Obtain a coagulation profile (INR or PT, PTT, fibrinogen, fibrin split products) in moderate or severe envenomation. Repeat periodically (every 6 hours or as clinically indicated). Because persistent or recurrent coagulopathy may occur, inpatients who develop an initial coagulopathy the recovers with antivenom, it may be advisable to monitor hematologic parameters weekly as an outpatient for the first 2 weeks after snakebite, particularly after pit viper envenomation (Boyer et al, 1999).
    2) WHOLE BLOOD CLOTTING TEST: If PT/INR and PT cannot be performed readily and the patient has no history of coagulopathies, a method to determine whole blood clotting can be done at the bedside with a few millimeters of venous blood placed in a new, clean, dry, glass tube (or bottle). The steps are as follows and may be useful if the species is unknown or difficult to identify:
    1) Place a few millimeters of venous blood in a tube;
    2) Leave undisturbed for 20 minutes at room temperature;
    3) Tip the vessel once:
    a) If blood is still liquid and runs out it is indicative of a venom-induced coagulopathy.
    b) Inaccurate results may occur if the vessel had been cleaned previously with detergent. Incoagulable blood is more frequently associated with viper envenomations.
    a) FALSE NEGATIVE results could occur if clot identification is read beyond 20 minutes (Stone et al, 2006).
    b) FALSE POSITIVE results could occur if polypropylene or polyethylene tubes are used instead of glass (Stone et al, 2006).
    1) A blinded methodological study was conducted to determine the potential effectiveness of various plastic containers as compared to glass in performing the whole blood clotting time (WBCT) (for 20 minutes) in envenomed patients. An initial pilot study demonstrated that WBCT without venom was significantly different between glass and various plastic containers (ie, polypropylene, polyethylene and polycarbonate). Polypropylene and plain polyethylene were considered unsuitable for further testing because of their prolonged clotting times of greater than 60 minutes in the presence of venom. The findings further suggested that various venom concentrations (0 ng/mL to 100,000 ng/ml were initially tested) could significantly alter the clotting time. No clotting was observed in either the glass or polycarbonate tube for venom concentrations above 100 ng/mL. Samples of 0 ng/mL and 10 ng/mL were used in the study because they clotted in 20 minutes. Polycarbonate (mean time of 29.5 minutes in the presence of venom) was considered a suitable alternative to glass if the threshold for clot identification was increased to 35 minutes. However, the authors concluded that differentiating between various plastic materials may be difficult and polycarbonate tubes may not be readily available in all healthcare facilities; therefore, the authors recommended the continued use of glass tubes (Stone et al, 2006).
    a) LIMITATIONS: Although glass tubes have been found to be sensitive and specific indicators of severe coagulopathy, false negative results could occur if the test results are read beyond the 20 minute threshold time. Other potential limitations could include: measurement bias of clot size, container volumes were not standardized, and use of one venom type (Pseudechis australis) may influence extrapolation of findings to other venom types.
    c) If there is any doubt, repeat the test and include a "control" (blood from an unexposed individual) (Anon, 1999).
    C) BLOOD/SERUM CHEMISTRY
    1) Serum electrolyte and creatine kinase (CPK) levels should be done in moderate or severe envenomation. Repeat as clinically indicated.
    2) Monitor renal function (blood urea nitrogen, creatinine) following severe envenomation. Acute renal failure is the most common cause of death following Bothrops envenomations in South America (Meier & White, 1995).
    D) ACID/BASE
    1) Obtain blood gases or pulse oximetry and repeat as clinically indicated.
    E) OTHER
    1) Type and hold blood for cross-match in cases of severe envenomation.
    4.1.3) URINE
    A) URINALYSIS
    1) Perform urinalysis to evaluate for hematuria, myoglobinuria, and/or proteinuria.
    4.1.4) OTHER
    A) OTHER
    1) MONITORING
    a) In severe Bothrops envenomations, an electrocardiogram is indicated.
    b) Intracompartmental pressure monitoring should be performed in cases of suspected compartment syndrome or extensive swelling (Meier & White, 1995).

Methods

    A) ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
    1) BOTHROPS: In one in vitro study, ELISA was used to evaluate the possible immunological differences among various venoms, to explain the potential variations in neutralization that occurred with various venoms (Zamuner et al, 2004). Indirect ELISA has also been used to compare the antigenic cross-reactivity of various venoms (Camey et al, 2002).
    B) IMMUNOASSAY
    1) BOTHROPS: Serum enzyme immunoassay can measure serum venom antigen concentration. In one study, quantification of venom levels were based on a B. jararaca venom standard curve ranging from 0.1 to 500 ng/mL (diluted to 1/10 in phosphate-buffered saline, pH 7.4, containing 1% of normal rabbit serum) (Franca et al, 2003; Cardoso et al, 1993).
    C) ELECTROPHORESIS
    1) Venom from B. asper was analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and two-dimensional gel electrophoresis, which revealed a complex protein pattern in the venom. In general, the authors suggested that this technique could be a useful tool to characterize snake venoms and to detect ontogenetic and geographic variations in venom protein composition (Saravia et al, 2001).

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.6) DISPOSITION/BITE-STING EXPOSURE
    6.3.6.1) ADMISSION CRITERIA/BITE-STING
    A) Any patient with significant or worsening local effects, or any signs of coagulopathy should be admitted to a healthcare facility for treatment and close monitoring.
    6.3.6.2) HOME CRITERIA/BITE-STING
    A) There is no role for home management of a snake bite.
    6.3.6.3) CONSULT CRITERIA/BITE-STING
    A) A medical toxicologist, toxinologist or poison center should be consulted in the event of a Latin American snake envenomation.
    6.3.6.5) OBSERVATION CRITERIA/BITE-STING
    A) All patients bitten by Latin American snakes should be evaluated in a healthcare facility and observed for 8 to 12 hours.

Monitoring

    A) Monitor the bite site for progression of swelling every 15 minutes.
    B) Monitor serial complete blood count, including platelets, coagulation profile (INR or PT, PTT, fibrinogen, fibrin split products) every 4 hours.
    C) Serum electrolytes, renal function and creatine kinase (CPK).
    D) Laboratory work should be repeated periodically, as indicated. Obtain a urinalysis, and type and hold for cross-match in severe envenomation.

Summary

    A) ENVENOMATION: A single bite can cause severe or even lethal envenomation. However, about 30% to 45% of pit viper bites in Central American do not result in envenomation.

Minimum Lethal Exposure

    A) BOTHROPS
    1) Bothrops are frequently associated with bites in both Central and South America. Deaths associated with Bothrops envenomations are usually attributable to renal failure, hypotension (cardiovascular shock), severe bleeding, and septicemia. Serum venom levels appear to correlate with the severity of envenoming, and absorption varies according to the location of the bite (eg, limb, trunk, head) (Franca et al, 2003; Meier & White, 1995). The Bothrops asper species is also abundant in Mexico (Meier & White, 1995).
    B) CROTALUS
    1) CENTRAL AMERICA: In general, these snakes (ie, Crotalus durissus durissus) produce mild envenomations, compared to subspecies found in South America (Meier & White, 1995).
    2) SOUTH AMERICA: Crotalus (c. d. terrificus) snake bites are responsible for producing neurotoxic, hematologic, and myotoxic effects. In this geographical area, fatalities have resulted from systemic myotoxicity, which can result in myoglobinuric acute renal failure (Meier & White, 1995).

Maximum Tolerated Exposure

    A) SUMMARY
    1) In general, pit vipers produce local effects rapidly following envenomation. The severity of envenoming is usually dependent on the amount of venom injected, the number of bites, and the route of the injection (eg, intramuscularly, subcutaneously), and the overall size of the victim (ie, children usually develop more severe envenomings compared to adults) (Meier & White, 1995).
    B) CROTALUS
    1) MEXICO: The genera Crotalus and Sistrurus (rattlesnakes) are found throughout Mexico. Local symptoms of pit viper envenomations can include pain, swelling, ecchymosis and bleeding from the fang marks. In general, these envenomations can produce the following systemic effects: alterations in mental status, bleeding, coagulopathy, hypotension, severe tachycardia, and respiratory compromise (Meier & White, 1995).
    2) CENTRAL AMERICA: Crotalus species found in Central America, primarily consist of Crotalus durissus durissus. In general, these snakes produce mild envenomations as compared to subspecies found in South America. Following envenomation local effects can include edema, bleeding and necrosis. Systemic effects can result in coagulopathy, extensive bleeding, hypovolemic shock and renal failure (Meier & White, 1995).
    3) SOUTH AMERICA: Crotalus (c. d. terrificus) snake bites are responsible for producing neurotoxic, hematologic, and myotoxic effects. Unlike Crotalus species found in Central America, systemic myotoxicity can be severe and myoglobinuric acute renal failure is a common cause of death in this region (Meier & White, 1995).
    C) LACHESIS SNAKEBITES
    1) Human snakebites by this species are rarely reported in the literature in Central America. Of those cases reported, neurotoxic activity is usually present, which can result in hypotension (due to vagal stimulation), drowsiness, abdominal pain, vomiting and diarrhea. If envenomation is severe, cardiovascular toxicity and shock can lead to death (Meier & White, 1995).
    2) Although the Lachesis (bushmaster) is responsible for less than 10% of snakebites in South America, it can produce similar envenomation effects as the Bothrops (Meier & White, 1995).

Toxicity Information

    7.7.1) TOXICITY VALUES
    A) CENTRAL AND SOUTH AMERICAN CROTALINAE

General Bibliography

    1) Alberts MB, Shalit M, & LoGalbo F: Suction for venomous snakebite: a study of "mock venom" extraction in a human model. Ann Emerg Med 2004; 43(2):181-186.
    2) Amaral CFS, Campolina D, Dias MB, et al: Tourniquet ineffectiveness to reduce the severity of envenoming after crotalus durissus snake bite in belo horizonte, minas gerais, brazil. Toxicon 1998; 36(5):805-808.
    3) Amaral CF, da Silva OA, & Lopez M: Afibrinogenemia follwoing snake bite (Crotalus durissus terrificus). Am J Trop Med Hyg 1980; 29:1453-1455.
    4) Amaral CFS, Campolina D, Dias MB, et al: Time factor in the detection of circulating whole venom and crotoxin and efficacy of antivenom therapy in patients envenomed by crotalus durissus. Toxicon 1997; 35(5):699-704.
    5) American Zoo and Aquarium Association: Antivenom Index. American Zoo and Aquarium Association. Silver Spring, MD. 2009. Available from URL: http://www.aza.org/ai/index.cfm. As accessed 2009-04-13.
    6) Anon: WHO/SEARO guidelines for clinical management of snake bites. So Asian J Trop Med Pub Health 1999; 30 (S1):1-85.
    7) Avila GC, Estrada J, & Garcia JP: Picados de vibora de cascabel: revision de casos atendidos en el Hospital General del Estado. Plana Medica 1980; 17:35-46.
    8) Avila-Aguero ML, Paris MM, Hu S, et al: Systemic cytokine response in children bitten by snakes in Costa Rica. Ped Emerg 2001; 17(6):425-429.
    9) Azevedo-Marques MM, Cupo P, Coimbra TM, et al: Myonecrosis, myoglobinuria and acute renal failure induced by South American rattlesnake (Crotalus durissus terrificus) envenomation in Brazil. Toxicon 1985; 23:631-636.
    10) Benvenuti LA, Franca FOS, & Barbaro KC: Pulmonary haemorrhage causing rapid death after bothrops jararacussu snakebite: a case report. Toxicon 2003; 42:331-334.
    11) Bond GR & Burkhart KK: Thryombocytopenia following timber rattlesnake envenomation. Ann Emerg Med 1997; 310:40-44.
    12) Borkow G, Gutierrez JM, & Ovadia M: Inhibition of toxic activities of Bothrops asper venom and other crotalid snake venoms by a novel neutralizing mixture. Toxicol Appl Pharmacol 1997; 147:442-447.
    13) Boyer LV, Seifert SA, & Clark RF: Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 1999; 159:706-710.
    14) Bronstein AC, Russell FE, & Sullivan JB: Negative pressure suction in field treatment of rattlesnake bite (abstract). Vet Human Toxicology 1985; 28:297.
    15) Bronstein AC, Russell FE, & Sullivan JB: Negative pressure suction in the field treatment of rattlesnake bite victims (abstract). Vet Hum Toxicol 1986; 28:485.
    16) Brown CV, Rhee P, Chan L, et al: Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference?. J Trauma 2004; 56(6):1191-1196.
    17) Bucaretchi F, Herrera SRF, & Hyslop S: Accidents caused by Bothrops spp snakes in children (abstract). J Toxicol-Clin Toxicol 2001; 39:263-264.
    18) Bucaretchi F, de Capitani EM, Hyslop S, et al: Compartment syndrome after Bothrops jararaca snakebite: monitoring, treatment, and outcome. Clin Toxicol (Phila) 2010; 48(1):57-60.
    19) Bucknall NC: Electrical treatment of venomous bites and stings (letter). Toxicon 1991; 29:397-400.
    20) Budzynski AZ, Pandya BV, & Rubin RN: Fibrinogenolytic afibrinogenemia after envenomation by western diamondback rattlesnake (Crotalus atrox). Blood 1984; 63:1-14.
    21) Burgess JL & Dart RC: Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation. Ann Emerg Med 1991; 20:795-801.
    22) Caiaffa WT, Vlahov D, & Antunes CMF: Snake bite and antivenom complications in Belo Horizonte, Brazil. Trans Royal Soc Trop Med Hyg 1994; 88:81-85.
    23) Camey KU, Velarde DT, & Sanchez EF: Pharmacological characterization and neutralization of the venoms used in the production of bothropic antivenom in brazil. Toxicon 2002; 40:501-509.
    24) Camp NE: Drug- and toxin-induced Rhabdomyolysis. J Emerg Nurs 2009; 35(5):481-482.
    25) Cardoso JLC, Fan HW, & Franca FOS: Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in Sao Paulo, Brazil. Quartely J Med 1993; 86:315-325.
    26) Crane DB & Irwin JS: Rattlesnake bite of glans penis. Urology 1985; 26:50-52.
    27) Criddle LM: Rhabdomyolysis. Pathophysiology, recognition, and management. Crit Care Nurse 2003; 23(6):14-22, 24-26, 28.
    28) Dart RC, Goldner AP, & Lindsey D: Efficacy of delayed administration of crotalid antivenom and crystalloid fluids. Toxicon 1988; 26:1218-1221.
    29) Davidson TM: Intravenous rattlesnake envenomation. West J Med 1988; 148:45-47.
    30) Ekenback K, Hulting J, & Persson H: Unusual neurological symptoms in a case of severe crotalid envenomation. Clin Toxicol 1985a; 23:357-364.
    31) Ekenback K, Hulting J, Persson H, et al: Unusual neurological symptoms in a case of severe crotalid envenomation . Clin Toxicol 1985; 23(4-6):357-364.
    32) Erdman AR & Dart RC: Rhabdomyolysis. In: Dart RC, Caravati EM, McGuigan MA, et al, eds. Medical Toxicology, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, PA, 2004, pp 123-127.
    33) Franca FOS, Barbaro KC, Fan HW, et al: Envenoming by bothrops jararaca in brazil; association between venom antigenaemia and severity at admission to hospital. Transact Royal Soc Trop Med Hyg 2003; 97:312-317.
    34) Hall EL: Role of surgical intervention in the management of crotaline snake envenomation. Ann Emerg Med 2001; 37:175-180.
    35) Hardy D: Bothrops asper (Viperidae) snakebite and field researchers in Middle America. Biotropica 1994; 26:198-207.
    36) Homsi E, Barreiro MF, Orlando JM, et al: Prophylaxis of acute renal failure in patients with rhabdomyolysis. Ren Fail 1997; 19(2):283-288.
    37) Howe NR & Meisenheimer JL Jr: Electric shock does not save snakebitten rats. Ann Emerg Med 1988; 17:245-256.
    38) Huerta-Alardin AL, Varon J, & Marik PE: Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care 2005; 9(2):158-169.
    39) Jorge MT, Cardoso JLC, Castro SCB, et al: A randomized 'blinded' comparison of two does of antivenom in the treatment of bothrops envenoming in sao paulo, brazil. Roy Soc Trop Med Hyg 1995; 89:111-114.
    40) Jorge MT, Sano-Martins IS, Tomy SC, et al: Snakebite by the bushmaster (lachesis muta) in brazil: Case report and review of the literature. Toxicon 1997; 35(4):545-554.
    41) Kasilo OJ: Poisonous snakes and insect bites. Bulletin: Dept of Pharm Drug & Toxicol Info Services, University of Zimbabwe 1990; 22:1.
    42) Kornalik F & Vorlova Z: Non-specific therapy of a hemorrhagic diathesis after a bite by a young Bothrops asper (Barba amarilla): a case report. Toxicon 1990; 28:1497-1501.
    43) Laing GD, Yarleque A, Marcelo A, et al: Preclinical testing of three south american antivenoms against the venoms of five medically-important peruvian snake venoms. Toxicon 2004; 44:103-106.
    44) Lavonas EJ, Ruha AM, Banner W, et al: Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2-2.
    45) Lieberman P, Nicklas R, Randolph C, et al: Anaphylaxis-a practice parameter update 2015. Ann Allergy Asthma Immunol 2015; 115(5):341-384.
    46) Lieberman P, Nicklas RA, Oppenheimer J, et al: The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126(3):477-480.
    47) Malbranque S, Piercecchi-Marti MD, Thomas L, et al: Fatal diffuse thrombotic microangiopathy after a bite by the "Fer-de-Lance" pit viper (Bothrops lanceolatus) of Martinique. Am J Trop Med Hyg 2008; 78(6):856-861.
    48) McKinney PE: Out-of-hospital and interhospital management of crotaline snakebite. Ann Emerg Med 2001; 37:168-174.
    49) Meier J & White J: ., Handbook of Clinical Toxicology and Animal Venoms and Poisons, CRC Press, Boca Raton, FL, 1995a.
    50) Meier J & White J: Handbook of Clinical Toxicology and Animal Venoms and Poisons, CRC Press, Boca Raton, FL, 1995.
    51) Milani R, Jorge MT, Ferraz FP, et al: Snake bites by the jararacucu (bothrops jararacussu): clinicopathological studies of 29 proven cases in sao paulo state, brazil. QJ Med 1997; 90:323-334.
    52) Mosquera A, Idrovo LA, Tafur A, et al: Stroke following bothrops spp. snakebite. Neurology 2003; 60(10):1577-1580.
    53) National Heart,Lung,and Blood Institute: Expert panel report 3: guidelines for the diagnosis and management of asthma. National Heart,Lung,and Blood Institute. Bethesda, MD. 2007. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
    54) Nicoleti AF, Medeiros CR, Duarte MR, et al: Comparison of Bothropoides jararaca bites with and without envenoming treated at the Vital Brazil Hospital of the Butantan Institute, State of Sao Paulo, Brazil. Rev Soc Bras Med Trop 2010; 43(6):657-661.
    55) Nowak RM & Macias CG : Anaphylaxis on the other front line: perspectives from the emergency department. Am J Med 2014; 127(1 Suppl):S34-S44.
    56) Oliveira FN, Brito MT, Morais IC, et al: Accidents caused by Bothrops and Bothropoides in the State of Paraiba: epidemiological and clinical aspects. Rev Soc Bras Med Trop 2010; 43(6):662-667.
    57) Otero R, Nunez V, Osorio RG, et al: Ability of six latin american antivenoms to neutralize the venom of mapana equis (bothrops atrox) from antioquia and choco (colombia) . Toxicon 1995; 33(6):809-815.
    58) Otero-Patino R, Segura A, Herrera M, et al: Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia. Toxicon 2012; 59(2):344-355.
    59) Otero-Patino R: Epidemiological, clinical and therapeutic aspects of Bothrops asper bites. Toxicon 2009; 54(7):998-1011.
    60) Pardal PP, Souza SM, Cardoso JLC, et al: Clinical trial of two antivenoms for the treatment of bothrops and lachesis bites in the north eastern amazon region of brazil. Royal Soc of Trop Med 2004; 98:28-42.
    61) Pinho FM, Yu L, & Burdmann EA: Snakebite-induced acute kidney injury in Latin America. Semin Nephrol 2008; 28(4):354-362.
    62) Polderman KH: Acute renal failure and rhabdomyolysis. Int J Artif Organs 2004; 27(12):1030-1033.
    63) Product Information: CroFab(R) intravenous injection, crotalidae polyvalent immune fab (ovine) intravenous injection. BTG International Inc. (per manufacturer), West Conshohocken, PA, 2012.
    64) Product Information: diphenhydramine HCl intravenous injection solution, intramuscular injection solution, diphenhydramine HCl intravenous injection solution, intramuscular injection solution. Hospira, Inc. (per DailyMed), Lake Forest, IL, 2013.
    65) Product Information: dopamine hcl, 5% dextrose IV injection, dopamine hcl, 5% dextrose IV injection. Hospira,Inc, Lake Forest, IL, 2004.
    66) Richardson WH, Tanen DA, Tong TC, et al: Crotalidae polyvalent immune Fab (ovine) antivenom is effective in the neutralization of South American viperidae venoms in a murine model. Ann Emerg Med 2005; 45(6):595-602.
    67) Rodrigues Sgrignolli L, Florido Mendes GE, Carlos CP, et al: Acute kidney injury caused by bothrops snake venom. Nephron Clin Pract 2011; 119(2):c131-c136.
    68) Rosado-Lopez L & Laviada-Arrigunaga A: Ophidic accident. Report of 38 cases. Prensa Med Mex 1977; 42(9-10):409-412.
    69) Rossi MA, Peres LC, & de Paola F: Electron-microscopic study of systemic myonecrosis due to poisoning by tropical rattlesnake (Crotalus durissus terrificus) in humans. Arch Pathol Lab med 1989; 113:169-173.
    70) Russell FE, Walter FG, Bey TA, et al: Review Article: Snakes and snakebite in central america. Toxicon 1997a; 35(10):1469-1522.
    71) Russell FE, Walter FG, & Bey TA: Snakes and snakebite in Central America (review). Toxicon 1997; 35:1469-1522.
    72) Russell FE: A letter on electroshock for snakebite. Vet Hum Toxicol 1987; 29:320.
    73) Russell FE: Snake venom poisoning in the United States. Ann Rev Med 1980; 31:247-259.
    74) Santoro ML, Sano-Martins IS, Fan HW, et al: Haematological evaluation of patients bitten by the jararaca, Bothrops jararaca, in Brazil. Toxicon 2008; 51(8):1440-1448.
    75) Saravia P, Rojas E, Escalante T, et al: The venom of bothrops asper from guatemala: toxic activities and neutralization by antivenoms. Toxicon 2001; 39:401-405.
    76) Silveira PVP & Nishioka SDA: South american rattlesnakes bite in a brazilian teaching hospital. Clinical and epidemiological study of 87 cases, with analysis of factors predictive of renal failure. Transact Royal Soc Trop Med Hyg 1992; 86:562-564.
    77) Stone R, Seymour J, & Marshall O: Plastic containers and the whole-blood clotting test: glass remains the best option. Trans R Soc Trop Med Hyg 2006; 100(12):1168-1172.
    78) Theakston RDG, Laing GD, Fielding CM, et al: Treatment of snake bites by bothrops species and lachesis muta in eucador: laboratory screening of candidate antivenoms. Transact Royal Soc Trop Med 1995; 89:550-554.
    79) Thomas L, Tyburn B, & Lang J: Early infusion of a purified monospecific F(ab')2 antivenom serum for Bothrops lanceolatus bites in Martinique (letter). Lancet 1996; 347:406.
    80) Torres JR, Torres MA, & Arroyo-Parejo MA: Coagulation disorders in bushmaster envenomation (letter). Lancet 1995; 346:449-450.
    81) Torrez PQ, Duarte MR, Franca FO, et al: First report of an accident with the speckled forest pit viper (Bothriopsis taeniata) in Brazil. Rev Soc Bras Med Trop 2009; 42(3):342-344.
    82) US Department of the Navy: Poisonous snakes of the world, Dover Publications Inc, New York, 1991.
    83) Vanden Hoek,TL; Morrison LJ; Shuster M; et al: Part 12: Cardiac Arrest in Special Situations 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. American Heart Association. Dallas, TX. 2010. Available from URL: http://circ.ahajournals.org/cgi/reprint/122/18_suppl_3/S829. As accessed 2010-10-21.
    84) Vanholder R, Sever MS, Erek E, et al: Rhabdomyolysis. J Am Soc Nephrol 2000; 11(8):1553-1561.
    85) Walter LA & Catenacci MH: Rhabdomyolysis. Hosp Physician 2008; 44(1):25-31.
    86) Zamuner SR, da Cruz-Hofling MA, Corrado AP, et al: Comparison of the neurotoxic and myotoxic effects of Brazilian bothrops venoms and their neutralization by commercial antivenom. Toxicon 2004; 44:259-271.
    87) Zamuner SR, Gutierrez JM, & Muscara MN: Bothrops asper and Bothrops jararaca snake venoms trigger microbicidal function of peritoneal leukocytes in vivo. Toxicon 2001; 39:1505-1513.
    88) Zugaib M, de Barros ACS, & Bittar RE: Abruptio placentae following snake bite. Am J Obstet Gynecol 1985; 151:754-755.
    89) da Silva IM & Tavares AM: Comparative evaluation of adverse effects in the use of powder trivalent antivenom and liquid antivenoms in Bothrops snake bites. Rev Soc Bras Med Trop 2012; 45(4):523-525.